首页> 外文期刊>Journal of Cancer Research and Therapeutics >Shenqifuzheng injection combined with chemotherapy in the treatment of advanced gastric cancer: A systematic review and meta-analysis
【24h】

Shenqifuzheng injection combined with chemotherapy in the treatment of advanced gastric cancer: A systematic review and meta-analysis

机译:参芪扶正注射液联合化疗治疗晚期胃癌的系统评价和荟萃分析

获取原文
       

摘要

Objective: The aim of this systematic review and meta-analysis was to evaluate the clinical efficacy of Shenqifuzheng (SQFZ) injection combined with chemotherapy in the treatment of advanced gastric cancer. Materials and Methods: We conducted an electronic search by using PubMed, EMBASE, ASCO, ESMO and Chinese National Knowledge Infratructure (CNKI), databases. The randomized controlled trials about Shenqifuzheng injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric cancer were reviewed and collected. Pooled odds ratio (OR) for the response rate and KPS improvement were calculated using the software MetaAnalyst 3.1. Results: Fifteen trials met our inclusion criteria and finally included in this meta-analysis. The objective response rate (ORR) in patients treated with Shenqifuzheng injection combined with chemotherapy was much higher than that of chemotherapy only (OR = 1.66, 95% CI: 1.20-2.29) with statistical significance (P 0.05). The pooled data showed the combined treatment can significant increase the Karnofsky score (KPS) compared with the chemotherapy only (OR = 3.74, 95% CI: 2.66-5.27 (P 0.05). Conclusion: SQFZ injection combined with chemotherapy treatment regimen can improve the clinical efficacy and performance status in patients with advanced gastric cancer compared with chemotherapy alone.
机译:目的:本系统综述和荟萃分析的目的是评估参芪扶正注射液联合化学疗法治疗晚期胃癌的临床疗效。材料和方法:我们使用PubMed,EMBASE,ASCO,ESMO和中国国家知识基础设施(CNKI)数据库进行了电子搜索。回顾并收集了参芪扶正注射液联合化学疗法与单纯化学疗法治疗晚期胃癌的随机对照试验。使用软件MetaAnalyst 3.1计算响应率和KPS改善的合并比值比(OR)。结果:15项试验符合我们的纳入标准,最终纳入了这项荟萃分析。参芪扶正注射液联合化疗患者的客观缓解率(ORR)远高于单纯化疗(OR = 1.66,95%CI:1.20-1.29),具有统计学意义(P <0.05)。汇总数据显示,与单纯化疗相比,联合治疗可显着提高卡氏评分(KPS)(OR = 3.74,95%CI:2.66-5.27(P <0.05)。结论:SQFZ注射液联合化疗方案可改善与单纯化疗相比,晚期胃癌患者的临床疗效和表现状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号